Modern pharmacotherapy of type 2 diabetes mellitus: focus on empagliflozin

DOI: https://doi.org/10.29296/25877305-2021-12-08
Download full text PDF
Issue: 
12
Year: 
2021

Associate Professor V. Skvortsov(1), MD; Professor B. Levitan(2), MD; A. Sabanov(1), MD; E.
Skvortsova(1); R. Bangarov(1) (1)Volgograd State Medical University, Ministry of Health of Russia
(2)Astrakhan State Medical University

In the current practice, the treatment of type 2 diabetes should be aimed at achieving glycemic control, and the effect on other risk factors for diseases of the cardiovascular system: increased body weight, hypertension, hypoglycemia. Jardins is the first effective hypoglycemic drug of the new generation, which reduces the risk of mortality from cardiovascular disease in patients with type 2 diabetes and concomitant diseases.
Keywords: 
endocrinology
therapy
empaglyphlosin
diabetes mellitus type 2
diseases of the cardiovascular system

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Inzucchi S.E. et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes, Obes Metab. 2020; 22 (4): 631–9. DOI: 10.1111/dom.13938
  2. Instruktsija po meditsinskomu primeneniju lekarstvennogo preparata Empagliflozin. Registratsionnoe udostoverenie LP-002755 ot 2015 g. [Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Empagliflozin. Registratsionnoe udostoverenie LP-002755 ot 2015 g. (in Russ.)].
  3. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can J Diabetes. 2016; 40 (3): 193–5. DOI: 10.1016/j.jcjd.2016.02.006
  4. Bailey C.I. The challenge of managing coexistent type 2 diabetes and obesity. BMJ. 2011; 342: d1996. DOI: 10.1136/bmj.d1996
  5. White W.B., Cannon C.P., Heller S.R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327–35. DOI: 10.1056/NEJMoa1305889
  6. Nathan D.M., DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014; 37 (1): 9–16. DOI: 10.2337/dc13-2112
  7. Bloomgarden Z.T. Cardiovascular disease in diabetes. Diabetes Care. 2008; 31 (6): 1260–6. DOI: 10.2337/dc08-zb06
  8. Grempler R., Thomas L., Eckhardt M. et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT2) inhibitor: sharacterisation and comparison with other SGLT2 inhibitors. Diabetes Obes Metab. 2012; 14 (1): 83–90. DOI: 10.1111/j.1463-1326.2011.01517.x
  9. Govan L., Wu O., Lindsay R. et al. How Do Diabetes Models Measure Up? A Review Of Diabetes Economic Models and ADA Guidelines. JHEOR. 2015; 5 (3): 132–52. DOI: 10.36469/9831
  10. Häring H.U. et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes care. 2014; 37 (6): 1650–9. DOI: 10.2337/dc13-2105
  11. Dedov I.I., Shestakova M.V., Galstjan G.R. i dr. Algoritmy spetsializirovannoj meditsinskoj pomoschi bol'nym saharnym diabetom, 7-izd. Saharnyj diabet. 2015; 18 (15): 1–112 [Dedov I.I., Shestakova M.V., Galstyan G.R. et al. Standards of specialized diabetes care (7th edition). Diabetes Mellitus. 2015; 18 (15): 1–112 (in Russ.)]. DOI: 10.14341/DM20151S1-112
  12. Barykina I.N., Salasjuk A.S., Smirnova V.O. Otchet o nauchno-issledovatel'skoj rabote «Farmakoekonomicheskij analiz primenenija lekarstvennogo preparata Empagliflozin (empagliflozin) pri lechenii saharnogo diabeta 2 tipa v Rossijskoj Federatsii». Volgograd, 2016 [Barykina I.N., Salasyuk A.S., Smirnova V.O. Otchet o nauchno-issledovatel’skoi rabote «Farmakoekonomicheskii analiz primeneniya lekarstvennogo preparata Empagliflozin (empagliflozin) pri lechenii sakharnogo diabeta 2 tipa v Rossiiskoi Federatsii». Volgograd, 2016 (in Russ.)].
  13. Amosova M.V., Fadeev V.V. Empagliflozin – novoe pokazanie k primeneniju – povorotnyj moment v lechenii saharnogo diabeta 2-go tipa. Meditsinskij sovet. 2017; 3: 38–43 [Amosova M.V., Fadeev V.V. A new indication for empagliflozin: turning point in the treatment of type 2 diabetes. Meditsinskiy sovet = Medical Council. 2017; 3: 38–43 (in Russ.)]. DOI: 10.21518/2079-701X-2017-3-38-43
  14. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129–200. DOI: 10.1093/eurheartj/ehw128
  15. Federal'nyj zakon «Ob obraschenii lekarstvennyh sredstv» ot 12.04.2010 №61-FZ [Federal’nyi zakon «Ob obrashchenii lekarstvennykh sredstv» ot 12.04.2010 №61-FZ (in Russ.)]. Dostupno / Available from: http://www.consultant.ru/document/cons_ doc_LAW_99350/